We take unique approaches to I&I (inflammation and immunology) research. Current immunotherapies remove excess pro-inflammatory molecules or deplete malignant immune cells. Instead, we seek to induce anti-inflammatory immune cell phenotypes using the body's natural response. Our approach can be useful for various autoimmune and inflammatory diseases, including type 1 diabetes, rheumatoid arthritis, IBD, multiple sclerosis, and infectious diseases.

We are keen to develop new cancer medicines with bioengineering methods. Cancer immunotherapy is a very promising approach used in the clinic. However, current therapies are not effective for every patient and are prone to toxicities. We are developing technologies that can deliver cancer drugs specifically to the tumour. Our targeted immunotherapy will improve the safety and efficacy of current treatments. Our goal is to translate our technologies to the clinic. We improve immune checkpoint inhibitors, cytokine therapies, CAR-T cells and TCR-T cells. We have ongoing pharma companies collaboration and clinical translational activities. Ishihara founded a company called ArrowImmune Inc.

Using our platform technology to deliver antigen to a specific organ and cells, we are now investigating a new idea of efficient antigen recognition for vaccine development.